{"analyses":[{"ciLowerLimit":"42.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"66.8","groupIds":["OG000"],"nonInferiorityType":"OTHER","paramType":"Exact method for binomial distributions","paramValue":"54.9"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Responders - CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Responders - VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Responders - PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).","groups":[{"description":"Participants began oral administration of ruxolitinib at 5 mg BID; if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID. Participants did receive prednisone 2.5 mg/kg per day orally (PO) or methylprednisolone 2.0 mg/kg per day IV.","id":"OG000","title":"Ruxolitinib in Combination With Corticosteroids"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy Evaluable Participants who had a CR, VGPR, or PR at Day 28 response assessment or other response assessments within ± 2 days of Day 28, on or before the start of new anti-GVHD therapy","reportingStatus":"POSTED","timeFrame":"From baseline to Day 28","title":"Overall Response Rate (ORR) at Day 28","type":"PRIMARY","unitOfMeasure":"Participants"}